[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
Kalenka
Armin
A
D003029:Coagulants / Q000191:economics / Q000627:therapeutic use*; D003422:Critical Care / Q000191:economics* / Q000639:trends; D015942:Factor VIIa / Q000191:economics / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D011486:Protein C / Q000191:economics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy* / Q000191:economics / Q000401:mortality
D003029:Coagulants; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; D015942:Factor VIIa; C421124:drotrecogin alfa activated